Researchers sought to determine whether a plerixafor-sparing regimen would prevent an increase in mobilization failures among patients with MM undergoing HCT.

In part 2 of our interview with Surbhi Sidana, MD, MBBS, American Society of Hematology and Stanford University, she delves ...

During a Case-Based Roundtable® event, Saad Z. Usmani, MD, FACP, MBA, discussed CAR T-cell therapy as third-line therapy for ...

Charley Steiner's multiple myeloma is in remission, marking a significant milestone in his private cancer journey. Jack Jones ...

Sarclisa in combination with the VRd regiment was superior to VRd alone in improving survival in stem cell transplant ...

Explore a discovery from researchers that could one day help tailor immunotherapy treatments for patients with multiple ...

Publication shows that OGM can resolve translocation partners involving MYC in multiple myeloma (MM) more effectively than current methodsThe ...

This study explored the safety and efficacy of a CXCR2 agonist and plerixafor for mobilization of HSCs for hematopoietic stem cell transplantation in patients with MM.

Darzalex will now be available to patients with newly diagnosed multiple myeloma eligible for autologous stem cell transplant ...

In separate, live virtual events, Doris Hansen, MD, and Leyla O. Shune, MD, discuss options for a patient with ...

Multiple myeloma is a type of cancer of the bone marrow. The cells in the bone marrow, called plasma cells, stop responding ...

Revlimid (lenalidomide) is a brand-name oral capsule prescribed to treat multiple myeloma and certain other blood cell cancers in adults. This article covers topics such as side effects ...